MergerNov 10, 2026, 04:51 PM
Mentari Therapeutics Completes Merger with InMed Pharmaceuticals
AI Summary
Mentari Therapeutics, Inc. (formerly InMed Pharmaceuticals Inc.) announced the closing of its business combination with Mentari Therapeutics, Inc. The combined entity will operate under the name Mentari Therapeutics, Inc. and will focus on developing therapies for migraine prevention, with InMed's legacy cannabinoid assets being managed through a Contingent Value Rights (CVR) agreement. The transaction involved a reverse stock split for InMed and significant pre-closing financings for Mentari, resulting in former Mentari stockholders holding approximately 99.0% of the combined company.
Key Highlights
- Mentari Therapeutics, Inc. (formerly InMed Pharmaceuticals Inc.) completed a business combination with Mentari Therapeutics, Inc.
- The combined company will operate as Mentari Therapeutics, Inc., focusing on migraine prevention therapies.
- Former InMed stockholders will own approximately 1.0% of the combined company, while former Mentari stockholders will own approximately 99.0% post-transaction.
- The Exchange Ratio was 0.20065 shares of InMed common stock for each share of Mentari common stock.
- Mentari secured $490.0 million in aggregate gross proceeds from pre-closing financings.
- InMed underwent a one-for-ten reverse stock split prior to the merger.
- InMed's legacy cannabinoid-based product candidates are subject to a Contingent Value Rights (CVR) agreement for potential future monetization.
Price Impact
More from INM